BIOMAT Database Logo BIOMAT Database Logo

Ursodeoxycholic acid for prevention of acute rejection in liver transplant recipients. 1990

H Persson, and S Friman, and T Scherstén, and J Svanvik, and I Karlberg

UI MeSH Term Description Entries
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D003524 Cyclosporins A group of closely related cyclic undecapeptides from the fungi Trichoderma polysporum and Cylindocarpon lucidum. They have some antineoplastic and antifungal action and significant immunosuppressive effects. Cyclosporins have been proposed as adjuvants in tissue and organ transplantation to suppress graft rejection. Cyclosporines
D003840 Deoxycholic Acid A bile acid formed by bacterial action from cholate. It is usually conjugated with glycine or taurine. Deoxycholic acid acts as a detergent to solubilize fats for intestinal absorption, is reabsorbed itself, and is used as a choleretic and detergent. Deoxycholate,Desoxycholic Acid,Kybella,Choleic Acid,Deoxycholic Acid, 12beta-Isomer,Deoxycholic Acid, 3beta-Isomer,Deoxycholic Acid, 5alpha-Isomer,Deoxycholic Acid, Disodium Salt,Deoxycholic Acid, Magnesium (2:1) Salt,Deoxycholic Acid, Monoammonium Salt,Deoxycholic Acid, Monopotassium Salt,Deoxycholic Acid, Monosodium Salt,Deoxycholic Acid, Sodium Salt, 12beta-Isomer,Dihydroxycholanoic Acid,Lagodeoxycholic Acid,Sodium Deoxycholate,12beta-Isomer Deoxycholic Acid,3beta-Isomer Deoxycholic Acid,5alpha-Isomer Deoxycholic Acid,Deoxycholate, Sodium,Deoxycholic Acid, 12beta Isomer,Deoxycholic Acid, 3beta Isomer,Deoxycholic Acid, 5alpha Isomer
D004341 Drug Evaluation Any process by which toxicity, metabolism, absorption, elimination, preferred route of administration, safe dosage range, etc., for a drug or group of drugs is determined through clinical assessment in humans or veterinary animals. Evaluation Studies, Drug,Drug Evaluation Studies,Drug Evaluation Study,Drug Evaluations,Evaluation Study, Drug,Evaluation, Drug,Evaluations, Drug,Studies, Drug Evaluation,Study, Drug Evaluation
D006084 Graft Rejection An immune response with both cellular and humoral components, directed against an allogeneic transplant, whose tissue antigens are not compatible with those of the recipient. Transplant Rejection,Rejection, Transplant,Transplantation Rejection,Graft Rejections,Rejection, Graft,Rejection, Transplantation,Rejections, Graft,Rejections, Transplant,Rejections, Transplantation,Transplant Rejections,Transplantation Rejections
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000208 Acute Disease Disease having a short and relatively severe course. Acute Diseases,Disease, Acute,Diseases, Acute
D000277 Adjuvants, Pharmaceutic Agents that aid or increase the action of the principle drug (DRUG SYNERGISM) or that affect the absorption, mechanism of action, metabolism, or excretion of the primary drug (PHARMACOKINETICS) in such a way as to enhance its effects. Adjuvant, Pharmaceutic,Adjuvant, Pharmaceutical,Adjuvants, Pharmaceutical,Pharmaceutic Adjuvant,Pharmaceutic Adjuvants,Pharmaceutical Adjuvant,Pharmaceutical Adjuvants
D000293 Adolescent A person 13 to 18 years of age. Adolescence,Youth,Adolescents,Adolescents, Female,Adolescents, Male,Teenagers,Teens,Adolescent, Female,Adolescent, Male,Female Adolescent,Female Adolescents,Male Adolescent,Male Adolescents,Teen,Teenager,Youths
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults

Related Publications

H Persson, and S Friman, and T Scherstén, and J Svanvik, and I Karlberg
Does prophylactic ursodeoxycholic acid treatment of liver transplant patients prevent acute rejection?
June 1998, Hepatology (Baltimore, Md.),
H Persson, and S Friman, and T Scherstén, and J Svanvik, and I Karlberg
Effect of ursodeoxycholic acid treatment for cholestasis in liver transplant recipients.
December 1995, Transplantation proceedings,
H Persson, and S Friman, and T Scherstén, and J Svanvik, and I Karlberg
Ursodeoxycholic acid modulates cyclosporin A oral absorption in liver transplant recipients.
January 2000, Fundamental & clinical pharmacology,
H Persson, and S Friman, and T Scherstén, and J Svanvik, and I Karlberg
Incidence of acute rejection in African-American liver transplant recipients.
June 1998, Transplantation proceedings,
H Persson, and S Friman, and T Scherstén, and J Svanvik, and I Karlberg
A prospective, randomized, double-blind trial evaluating the efficacy of ursodeoxycholic acid in prevention of liver transplant rejection.
July 1998, Liver transplantation and surgery : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society,
H Persson, and S Friman, and T Scherstén, and J Svanvik, and I Karlberg
Outcomes of acute rejection after interferon therapy in liver transplant recipients.
July 2004, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society,
H Persson, and S Friman, and T Scherstén, and J Svanvik, and I Karlberg
Alpha-glutathione-S-transferase in acute rejection of liver transplant recipients.
February 1998, Transplantation,
H Persson, and S Friman, and T Scherstén, and J Svanvik, and I Karlberg
HLA-G polymorphism (rs16375) and acute rejection in liver transplant recipients.
January 2014, Disease markers,
H Persson, and S Friman, and T Scherstén, and J Svanvik, and I Karlberg
Acute rejection in HCV-infected liver transplant recipients: The great conundrum.
November 2006, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society,
H Persson, and S Friman, and T Scherstén, and J Svanvik, and I Karlberg
Failure of ursodeoxycholic acid to prevent acute cellular rejection after liver transplantation.
August 1995, Journal of hepatology,
Copied contents to your clipboard!